This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Chapple ILC, Genco R et al. Diabetes and periodontal diseases: consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases. J Clin Periodontology 2013; 40 (suppl 14): 106–112. doi: 10.1902/jop.2013.1340011.ChappleILCGencoRDiabetes and periodontal diseases: consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases201340suppl 1410611210.1902/jop.2013.134001123631572Open DOISearch in Google Scholar
Epping L, Miesbach W, Nickles K, Eickholz P. Is gingival bleeding a symptom of type 2 and 3 von Willebrand disease? PLoS One 2018; 13(1): e0191291. doi: 10.1371/journal/pone.0191291.EppingLMiesbachWNicklesKEickholzPIs gingival bleeding a symptom of type 2 and 3 von Willebrand disease?2018131e019129110.1371/journal/pone.0191291Open DOISearch in Google Scholar
Brewer A, Correa ME, on behalf of the World Federation of Hemophilia Dental Committee. Guidelines for dental treatment of patients with inherited bleeding disorders. Treatment of Haemophilia, no. 40, May 2006. Available from https://www1.wfh.org/publication/files/pdf-1190.pdf (accessed 1 September 2022).BrewerACorreaMEon behalf of the World Federation of Hemophilia Dental CommitteeGuidelines for dental treatment of patients with inherited bleeding disorders40May2006Available from https://www1.wfh.org/publication/files/pdf-1190.pdf (accessed 1 September 2022).Search in Google Scholar
Connell NT, Flood VH, Brignardello-Petersen R, et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv 2021; 5(1): 301–325. doi: 10.1182/bloodadvances.2020003264.ConnellNTFloodVHBrignardello-PetersenRASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease20215130132510.1182/bloodadvances.2020003264780532633570647Open DOISearch in Google Scholar
Poveda Roda R, Bagan JV, Díaz Fernández, et al. Review of temporomandibular joint pathology. Part I: classification, epidemiology and risk factors. Med Oral Patol Oral Cir Bucal 2007; 12(4): E292–8. Available from http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1698-69462007000400006&lng=es&nrm=iso (accessed 26 September 2022).Poveda RodaRBaganJVDíaz FernándezReview of temporomandibular joint pathology. Part I: classification, epidemiology and risk factors2007124E2928Available from http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1698-69462007000400006&lng=es&nrm=iso (accessed 26 September 2022).Search in Google Scholar
Grushka M, Epstein JB, Gorsky M. Burning mouth syndrome. Am Fam Physician 2002; 65(2): 615–621. Available from https://www.aafp.org/pubs/afp/issues/2002/0215/p615.html (accessed 26 September 2022).GrushkaMEpsteinJBGorskyMBurning mouth syndrome2002652615621Available from https://www.aafp.org/pubs/afp/issues/2002/0215/p615.html (accessed 26 September 2022).Search in Google Scholar
Dahiya P, Kamal R, Kumar M, Gupta R, Chaudhary K. Burning mouth syndrome and menopause. Int J Prev Med 2013; 4(1): 15–20.DahiyaPKamalRKumarMGuptaRChaudharyKBurning mouth syndrome and menopause2013411520Search in Google Scholar
Ślebioda Z, Szponar E. Burning mouth syndrome – a common dental problem in perimenopausal women. Prz Menopauzalny 2014; 13 (3): 198–202. doi: 10.5114/pm.2014.43825.ŚlebiodaZSzponarEBurning mouth syndrome – a common dental problem in perimenopausal women201413319820210.5114/pm.2014.43825452036326327855Open DOISearch in Google Scholar
Osooli M, Donfield SM, Carlsson KS et al. Joint comorbidities among Swedish carriers of haemophilia: A register-based cohort study over 22 years. Haemophilia 2019; 25(5): 845–850. doi: 10.1111/hae.13831.OsooliMDonfieldSMCarlssonKSJoint comorbidities among Swedish carriers of haemophilia: A register-based cohort study over 22 years201925584585010.1111/hae.1383131411798Open DOISearch in Google Scholar
van Galen KPM, Timmer M, de Kleijn P, et al. Long-term outcome after joint bleeds in von Willebrand disease compared to haemophilia A: a post hoc analysis. Thromb Haemost 2018; 118(10): 1690–1700. doi: 10.1055/s-0038-1670704.van GalenKPMTimmerMde KleijnPLong-term outcome after joint bleeds in von Willebrand disease compared to haemophilia A: a post hoc analysis2018118101690170010.1055/s-0038-167070430273954Open DOISearch in Google Scholar
Négrier C, Mahlangu J, Lehle M, et al. Emicizumab prophylaxis in persons with mild or moderate hemophilia A: Results from the interim analysis of the HAVEN 6 study. Blood 2021; 138(1): 343. doi: 10.1182/blood-2021-146009.NégrierCMahlanguJLehleMEmicizumab prophylaxis in persons with mild or moderate hemophilia A: Results from the interim analysis of the HAVEN 6 study2021138134310.1182/blood-2021-146009Open DOISearch in Google Scholar
Hermans C, Négrier C, Lehle M, et al. Emicizumab prophylaxis for the treatment of people with moderate or mild haemophilia A without factor VIII inhibitors: Results from the primary analysis of the HAVEN 6 study [abstract]. ISTH 2022 Congress. Available from https://abstracts.isth.org/abstract/emicizumab-prophylaxis-for-the-treatment-of-people-with-moderate-or-mild-hemophilia-a-without-factor-viii-inhibitors-results-from-the-primary-analysis-of-the-haven-6-study/ (accessed 26 September 2022).HermansCNégrierCLehleMISTH 2022 Congress. Available from https://abstracts.isth.org/abstract/emicizumab-prophylaxis-for-the-treatment-of-people-with-moderate-or-mild-hemophilia-a-without-factor-viii-inhibitors-results-from-the-primary-analysis-of-the-haven-6-study/ (accessed 26 September 2022).Search in Google Scholar
National Library of Medicine (US). Emicizumab for severe von Willebrand disease (VWD) and VWD/haemophilia A (BCDI-XII). 15 August 2022-. Identifier: NCT05500807. Available from https://clinicaltrials.gov/ct2/show/NCT05500807?term=Hemlibra&draw=2&rank=5 (accessed 26 September 2022).National Library of Medicine (US)Available from https://clinicaltrials.gov/ct2/show/NCT05500807?term=Hemlibra&draw=2&rank=5 (accessed 26 September 2022).Search in Google Scholar
Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020; 26 (Suppl 6): 1–158. doi: 10.1111/14046.SrivastavaASantagostinoEDougallAWFH Guidelines for the Management of Hemophilia, 3rd edition202026Suppl 6115810.1111/14046Open DOISearch in Google Scholar
de Kleijn P, Duport G, Jansone K, et al; European Haemophilia Consortium and EAHAD Physiotherapy Committee. European principles of care for physiotherapy provision for persons with inherited bleeding disorders: Perspectives of physiotherapists and patients. Haemophilia 2022 May 4. doi: 10.1111/hae.14566. Online ahead of print.de KleijnPDuportGJansoneKEuropean Haemophilia Consortium and EAHAD Physiotherapy CommitteeEuropean principles of care for physiotherapy provision for persons with inherited bleeding disorders: Perspectives of physiotherapists and patients2022May410.1111/hae.14566Online ahead of print.35506491Open DOISearch in Google Scholar
Citla-Sridhar D, Sidonio RF, Ahuja SP. Bone health in haemophilia carriers and persons with von Willebrand disease: A large database analysis. Haemophilia 2022; 28(4): 671–678. doi: 10.1111/hae.14565.Citla-SridharDSidonioRFAhujaSPBone health in haemophilia carriers and persons with von Willebrand disease: A large database analysis202228467167810.1111/hae.1456535416396Open DOISearch in Google Scholar